F.D.A. Delays Action on Closely Watched Alzheimer ’s Drug

Eli Lilly ’s donanemab was expected to be approved this month, but the agency has decided to convene a panel of independent experts to evaluate the drug’s safety and efficacy.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Drugs (Pharmaceuticals) Alzheimer ' s Disease Eli Lilly and Company Food and Drug Administration donanemab Source Type: news